Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570813 | 0.87 | KDM4E (1.00) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL429276 | 0.87 | KDM4E (1.00) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6284934 | 0.85 | HSD17B10 (0.74) | KDM4EHSD17B10ALOX15TSHRKCNJ1 | |
| Hydrochloric Acid SCHEMBL2674609 | 0.85 | KDM4E (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8859868 | 0.85 | KDM4E (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL13833218 | 0.85 | KDM4E (1.00) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16571085 | 0.85 | KDM4E (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL11205570 | 0.85 | KDM4E (1.00) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| Water SCHEMBL7425166 | 0.85 | KDM4E (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4541214 | 0.83 | KDM4E (0.48) | KDM4ETSHRSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912988-B1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | KDM4E 2386/4885HSD17B10 1724/4885ALOX15 2297/4885 |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | KDM4E 481/4885HSD17B10 3473/4885ALOX15 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.